tbuckley/cabot-search huggingface dataset:
<i>De Novo</i> Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer
Authors: Saber Tadros, Surendra K. Shukla, Ryan J. King, Venugopal Gunda, Enza Vernucci, Jaime Abrego, Nina V. Chaika, Fang Yu, Audrey J. Lazenby, Lyudmyla Berim, Jean Grem, Aaron R. Sasson, Pankaj K. Singh
Journal: Cancer Research (2017)

Abstract Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, previous attempts at identifying and targeting the resistance mechanisms have not been very successful. By leveraging The Cancer Genome Atlas dataset, we identified lipid metabolism as the metabolic pathway that most significantly correlated with poor gemcitabine response in pancreatic cancer patients. Furthermore, we investigated the relationship between alterations in lipogenesis pathway and gemcitabine resistance by utilizing tissues from the genetically engineered mouse model and human pancreatic cancer patients. We observed a significant increase in fatty acid synthase (FASN) expression with increasing disease progression in spontaneous pancreatic cancer mouse model, and a correlation of high FASN expression with poor survival in patients and poor gemcitabine responsiveness in cell lines. We observed a synergistic effect of FASN inhibitors with gemcitabine in pancreatic cancer cells in culture and orthotopic implantation models. Combination of gemcitabine and the FASN inhibitor orlistat significantly diminished stemness, in part due to induction of endoplasmic reticulum (ER) stress that resulted in apoptosis. Moreover, direct induction of ER stress with thapsigargin caused a similar decrease in stemness and showed synergistic activity with gemcitabine. Our in vivo studies with orthotopic implantation models demonstrated a robust increase in gemcitabine responsiveness upon inhibition of fatty acid biosynthesis with orlistat. Altogether, we demonstrate that fatty acid biosynthesis pathway manipulation can help overcome the gemcitabine resistance in pancreatic cancer by regulating ER stress and stemness. Cancer Res; 77(20); 5503–17. ©2017 AACR.
リン脂質殻マイクロバブルによる人工および生体膜における分子配列の調節【Powered by NICT】
Authors: Carugo Dario, Aron Miles, Sezgin Erdinc, Bernardino de la Serna Jorge, K Kuimova Marina, Eggeling Christian, Stride Eleanor
Journal: Biomaterials (2017)
Big Data Not Yet Big Enough to Determine the Influence of Intracranial Pressure Monitoring on Outcome in Children With Severe Traumatic Brain Injury
Authors: Christopher M. Horvat, Patrick M. Kochanek
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors
Authors: Jennifer M. Sahni, Sylvia S. Gayle, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Salendra Singh, Steven T. Sizemore, Nicole A. Restrepo, Gurkan Bebek, Peter C. Scacheri, Vinay Varadan, Matthew K. Summers, Ruth A. Keri
Journal: Cancer Research (2017)

Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, making the discovery of novel therapeutic targets for this disease imperative. Our previous analysis of the molecular mechanisms of action of bromodomain and extraterminal protein inhibitors (BETi) in TNBC revealed these drugs cause multinucleation, indicating BET proteins are essential for efficient mitosis and cytokinesis. Here, using live cell imaging, we show that BET inhibition prolonged mitotic progression and induced mitotic cell death, both of which are indicative of mitotic catastrophe. Mechanistically, the mitosis regulator LIN9 was a direct target of BET proteins that mediated the effects of BET proteins on mitosis in TNBC. Although BETi have been proposed to function by dismantling super-enhancers (SE), the LIN9 gene lacks an SE but was amplified or overexpressed in the majority of TNBCs. In addition, its mRNA expression predicted poor outcome across breast cancer subtypes. Together, these results provide a mechanism for cancer selectivity of BETi that extends beyond modulation of SE-associated genes and suggest that cancers dependent upon LIN9 overexpression may be particularly vulnerable to BETi. Cancer Res; 77(19); 5395-408. ©2017 AACR.
2004英国高血压学会高血压治疗指南（BHS-IV）：概要
Authors: BryanWilliams, NeilRPoulter, PeterSSever, SimonMcGThom, MorrisJBrown, MarkDavis, GordonTMclnnes, JohnFPotter, 邱洪, 高润霖
Journal: BMJ (2004)

在高血压领域，不断出现的新证据已日益受到关注。例如：血压可作为心血管疾病的一个危险因素；改进生活方式对于预防和治疗高血压的重要意义；不同类型药物的有效性和安全性；高危高血压患者包括糖尿病患者的治疗；心血管疾病总体危险性评估的重要性以及使用他汀类药物所获得的额外益处。
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Authors: Suresh S. Ramalingam, James C.-H. Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne
Journal: Journal of Clinical Oncology (2017)

Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] –tyrosine kinase inhibitor selective for EGFR–tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC). Patients and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms. Results At data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected. Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.
Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
Authors: S I Tracy, M J Maurer, T E Witzig, M T Drake, S M Ansell, G S Nowakowski, C A Thompson, D J Inwards, P B Johnston, I N Micallef, C Allmer, W R Macon, G J Weiner, S L Slager, T M Habermann, B K Link, J R Cerhan
Journal: Blood Cancer Journal (2017)

We evaluated whether vitamin D insufficiency (VDI; 25(OH)D <20 ng/ml) was associated with adverse outcomes among follicular lymphoma (FL) patients using an observational prospective cohort study of 642 FL patients enrolled from 2002–2012. The median age at diagnosis was 60 years. At a median follow-up of 59 months, 297 patients (46%) had an event (progression, treatment failure), 78 had died and 42 (6.5%) had a lymphoma-related death. VDI was associated with inferior event-free survival (EFS) at 12 months (EFS12, odds ratio (OR)=2.05; 95% confidence interval (CI) 1.18–3.54), overall survival (OS, hazards ratio (HR)=2.35; 95%CI 1.37–4.02), and lymphoma-specific survival (LSS, HR=2.97; 95% CI 1.52–5.80) for the full cohort. Among patients treated with immunochemotherapy (IC), VDI was associated with inferior EFS12 (OR=3.00; 95% CI 1.26–7.13), OS (HR=2.86; 95% CI 1.39–5.85), and LSS (HR=2.96; 95% CI 1.29–6.79). For observed patients, VDI was associated with inferior OS (HR=2.85; 95% CI 1.20–6.76). For other therapies, VDI was associated with inferior OS (HR=3.06; 95% CI 1.01–9.24). Our work is the first to reveal an association of VDI with early clinical failure, and to demonstrate an association of VDI with adverse outcomes among patients who are observed or treated with therapies other than IC. Our findings suggest a potentially modifiable prognostic factor to address in patients with FL.
Abstract 19423: Rodent Hind Limb Collaterals Develop as Intertwined Strands Accompanied by Veins
Authors: Janina C Schwarz, Monique G van Lier, Elco Oost, Erik N Bakker, Jos A Spaan, Maria Siebes
Journal: Circulation (2015)

Background: The process of angiogenesis and collateral remodeling in response to rodent hind limb ischemia has been intensely studied at micro- as well as at macroscopic level. Yet, a detailed investigation of the three-dimensional (3D) collateral vessel architecture in this model is lacking. Methods: To stimulate collateral growth in the rat hind limb the femoral artery was ligated. After sacrifice at day 3, 7 or 28, the systemic circulation was flushed via the cannulated abdominal aorta, the vasculature was filled with fluorescent cast material, and the frozen limbs were embedded in black gel. Registered stacks of episcopic fluorescence images, acquired with a custom-built imaging cryomicrotome (24 μm 3 voxel resolution). High-resolution 3D-renderings of the vascular cast were obtained after deblurring. Multiple collateral arteries and veins were identified between the muscular branch of the femoral and the saphenous artery and vein and diameters were assessed in four regions (near the stem and re-entry, at the mid-zone, and just proximal to the re-union of individual collaterals) using a semi-automatic approach based on vesselness filtering. Results: The gracilis collaterals form a complex network of intertwined vessels with highly individual architecture. Both pre-existing and new small collateral loops were commonly bundled as pairs of artery and vein. In early arteriogenesis, these bundles exhibited a multitude of small sprouting side branches. Arterial diameter increased with ischemia duration from 108 μm in healthy to 130 μm in 7-days post-ligation legs and 182 μm in 28-days post-FAL limbs (p&lt;0.01) whereas collateral vein remained unchanged. Rather than an increasing number of long bridging collateral arteries over time, we noticed an increased arcade formation of paired arteries and veins. Conclusions: We examined 4 stages of neovascularization in 3D in high detail. Initial sprouting gave way to formation of intertwined collateral strands accompanied by veins. The proximity of collateral arteries to veins calls for investigation of the role of veins during arteriogenesis.
癌治療のための強化された腫瘍蓄積を有する高効率とclearable phototheranosticsとしてのフラーレン/光増感剤ナノベシクル【Powered by NICT】
Authors: Guan Mirong, Ge Jiechao, Wu Jingyi, Zhang Guoqiang, Chen Daiqin, Zhang Wei, Zhang Ying, Zou Toujun, Zhen Mingming, Wang Chunru, Chu Taiwei, Hao Xiaojuan, Shu Chunying
Journal: Biomaterials (2016)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Authors: Sébastien Anguille, Ann L. Van de Velde, Evelien L. Smits, Viggo F. Van Tendeloo, Gunnar Juliusson, Nathalie Cools, Griet Nijs, Barbara Stein, Eva Lion, Ann Van Driessche, Irma Vandenbosch, Anke Verlinden, Alain P. Gadisseur, Wilfried A. Schroyens, Ludo Muylle, Katrien Vermeulen, Marie-Berthe Maes, Kathleen Deiteren, Ronald Malfait, Emma Gostick, Martin Lammens, Marie M. Couttenye, Philippe Jorens, Herman Goossens, David A. Price, Kristin Ladell, Yoshihiro Oka, Fumihiro Fujiki, Yusuke Oji, Haruo Sugiyama, Zwi N. Berneman
Journal: Blood (2017)
Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation in the Real-World: The Fushimi AF Registry
Authors: Yamashita Yugo, Esato Masahiro, Chun Yeong‐Hwa, Tsuji Hikari, Wada Hiromichi, Hasegawa Koji, Ogawa Hisashi, Abe Mitsuru, Akao Masaharu
Journal: Circulation (2016)
Is It Necessary to Eliminate Adenosine Triphosphate Induced Non-Pulmonary Vein Foci after Pulmonary Vein and Superior Vena Cava Isolation?
Authors: Hama Yoshiyuki, Matsudo Yuji, Kuwahara Taishi, Hashimoto Osamu, Terabayashi Ikuto, Ge Bei, Tanaka Shuzo, Tonoike Norimasa, Hou Kyokushi, Sekine Tai, Fujimoto Yoshihide, Yamamoto Masashi, Himi Toshiharu
Journal: Circulation (2016)
Abstract 13260: Trends in Survival From In-hospital Cardiac Arrests During Nights and Weekends
Authors: Uchenna R Ofoma, Suresh Basnet, Andrea Berger, H L Kirchner, Saket Girotra
Journal: Circulation (2016)

Background: In-hospital cardiac arrest (IHCA) survival is worse during nights and weekends. Although survival and neurologic outcomes after IHCA have improved in recent years, it remains unknown whether the above trends are consistent in patients with IHCA during nights and weekends. Methods: We identified 151,071 adults at 470 U.S. hospitals in the Get with the Guidelines-Resuscitation registry during 2000-2014. Using multivariable logistic regression with generalized estimating equations, we examined temporal trends in survival to discharge and determined whether trends in IHCA differed during on-hours (Monday - Friday 7:00 am - 10:59 pm) vs. off-hours (Monday - Friday 11:00 pm - 6:59 am, Saturday-Sunday, all day). We also examined acute resuscitation and post-resuscitation survival as secondary outcomes. Results: Among 151,071 participants, 79,091 (52.4%) had an IHCA during off-hours. Risk-adjusted survival proportions improved over time in both groups ( on-hours : 16.0% in 2000, 25.2% in 2014; off-hours : 11.9% in 2000, 21.9% in 2014; P for trend &lt; .001 for both). However, temporal trends in survival did not differ between on-hours and off-hours both on absolute (P=0.75) and relative scale (P = .059, Table). Acute resuscitation survival improved significantly in both groups ( on-hours : 56.1% in 2000, 71% in 2014; off-hours : 46.9% in 2000, 68.2% in 2014; P for trend &lt; .001 for both) such that difference between on-hours and off-hours narrowed over time (P=0.02 absolute scale, P &lt; .001 relative scale, Table). In contrast, although post-resuscitation survival improved over time in both groups (P for trend &lt; .001), the absolute and relative differences persisted in both groups (Table). Conclusions: Despite a significant temporal reduction in acute resuscitation survival difference for IHCA during on-hours compared to off-hours, differences in overall survival persist between the groups, highlighting an important area for quality improvement.
放射性標識長循環ナノ粒子を用いた末梢動脈疾患における増強された透過性と保持効果の再評価【Powered by NICT】
Authors: G England Christopher, Im Hyung-Jun, Feng Liangzhu, Chen Feng, A Graves Stephen, Hernandez Reinier, Orbay Hakan, Xu Cheng, Y Cho Steve, J Nickles Robert, Liu Zhuang, Lee Dong Soo, Cai Weibo
Journal: Biomaterials (2016)
膵臓癌治療のためのナノキャリアベースドラッグデリバリーシステムを用いた増強された免疫原性細胞死の誘導【Powered by NICT】
Authors: Zhao Xiao, Yang Keni, Zhao Ruifang, Ji Tianjiao, Wang Xiuchao, Yang Xiao, Zhang Yinlong, Cheng Keman, Liu Shaoli, Hao Jihui, Ren He, W Leong Kam, Nie Guangjun
Journal: Biomaterials (2016)
5種類の処置周辺の経口抗凝固療法実施患者における心房細動のカテーテル・アブレーション後の無症状の脳虚血性病巣―拡散強調イメージング陽性の病巣および追跡調査の磁気共鳴映像法の予測因子―
Authors: Nakamura Kohki, Naito Shigeto, Sasaki Takehito, Minami Kentaro, Take Yutaka, Goto Eri, Shimizu Satoru, Yamaguchi Yoshiaki, Suzuki Naoko, Yano Toshiaki, Senga Michiharu, Kumagai Koji, Kaseno Kenichi, Funabashi Nobusada, Oshima Shigeru
Journal: Circulation (2016)
Effect of a Low Lysine Diet on Mammary-Tumor Formation in Strain C3H Mice
Authors: Florence R. White, Julius White
Journal: JNCI Journal of the National Cancer Institute (1944)

Journal Article Effect of a Low Lysine Diet on Mammary-Tumor Formation in Strain C3H Mice Get access Florence R. White, Florence R. White assistant biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Julius White Julius White senior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 1, August 1944, Pages 41–42, https://doi.org/10.1093/jnci/5.1.41 Published: 01 August 1944
Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care
Authors: Katherine E. Watkins, Allison J. Ober, Karen Lamp, Mimi Lind, Claude Setodji, Karen Chan Osilla, Sarah B. Hunter, Colleen M. McCullough, Kirsten Becker, Praise O. Iyiewuare, Allison Diamant, Keith Heinzerling, Harold Alan Pincus
Journal: JAMA Internal Medicine (2017)

Primary care offers an important and underutilized setting to deliver treatment for opioid and/or alcohol use disorders (OAUD). Collaborative care (CC) is effective but has not been tested for OAUD.
Pre- and Post-operative Simulation Using 3D Printed Model
Authors: Murakami Takashi, Hosono Mitsuharu, Sakaguchi Masanori, Morisaki Akimasa, Suehiro Yasuo, Nishimura Shinsuke, Yasumizu Daisuke, Sakon Yoshito, Shibata Toshihiko
Journal: Circulation (2016)
4T1同所性乳房腫瘍の転移を特異的に阻害すると効果的にするiTEPサリノマイシンナノ粒子【Powered by NICT】
Authors: Zhao Peng, Xia Guiquan, Dong Shuyun, Jiang Zhaong-Xing, Chen Mingnan
Journal: Biomaterials (2016)
Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.
Authors: Alan Loh Ho, Eric Jeffrey Sherman, Shrujal S. Baxi, Sofia Haque, Ai Ni, Cristina R. Antonescu, Nora Katabi, Luc G. Morris, Timothy An-thy Chan, David G. Pfister
Journal: Journal of Clinical Oncology (2016)

6096 Background: Recurrent/metastatic adenoid cystic carcinoma (R/M ACC) is incurable. Regorafenib (BAY 73-4506; Bayer) is a tyrosine kinase inhibitor (TKI) that targets receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR), each thought to be activated in ACC. In this phase II trial, we tested if regorafenib is an effective therapy for R/M ACC. Methods: Patients had incurable R/M ACC of any primary site. Evidence of disease progression on imaging performed within 6 months of enrollment ornew/worsening disease-related symptoms was required. Patients were started at 160 mg daily for 3 weeks in a 4-week cycle. To limit drug toxicities, the protocol was later amended to start patients at 120 mg daily; if dose reduction was not performed/required, escalation to 160 mg was allowed. There are two RECIST v1.1 evaluable primary endpoints: 1) the proportion of patients alive at 6 months without disease progression, and 2) best overall response rate. Among 38 patients, if at least 21 are alive and free of progression at 6 months, or at least 5 have a response, the study would be deemed positive. Results: 38 patients were registered. 15 were started at 160 mg. Only two of the 23 started at 120 mg were increased to 160 mg. No CRs or PRs have been observed. 17 have had SD for 6 months or more; only 1 of 8 patients currently on therapy has been treated < 6 months. Whole exome (16 tumors) and RNAseq (9 tumors) analyses were performed, results are pending. Conclusions: The study failed to meet the primary endpoints, but regorafenib may elicit disease control for a subset of ACC patients. Final clinical and exploratory analyses evaluating the genomic and transcriptomic landscape of ACCs are pending. Clinical trial information: NCT02098538.
Opening the Book on Maintenance of Certification
Authors: Steven E. Weinberger
Journal: Annals of Internal Medicine (2018)

Letters20 March 2018Opening the Book on Maintenance of CertificationSteven E. Weinberger, MDSteven E. Weinberger, MDAmerican College of Physicians, Philadelphia, Pennsylvania (S.E.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0643 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Schiffman brings up an important issue that has been raised by many physicians who have taken a maintenance of certification examination. One of the major points that the American College of Physicians has repeatedly raised to the American Board of Internal Medicine is the need to ensure the relevance of the questions on the secure examination. The American Board of Internal Medicine has recently been trying to make the examination more relevant by developing (and making public) a detailed question blueprint that is based on feedback from practicing clinicians about the importance of specific topics and how ...Reference1. American Board of Internal Medicine. Internal medicine maintenance of certification (MOC) examination blueprint. January 2018. Accessed at www.abim.org/~/media/ABIM%20Public/Files/pdf/exam-blueprints/maintenance-of-certification/internal-medicine.pdf on 18 October 2017. Google Scholar Author, Article, and Disclosure InformationAffiliations: American College of Physicians, Philadelphia, Pennsylvania (S.E.W.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-1853. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOpening the Book on Maintenance of Certification Steven E. Weinberger Opening the Book on Maintenance of Certification Philip L. Schiffman Metrics 20 March 2018Volume 168, Issue 6Page: 460KeywordsDisclosureSub-specialty care ePublished: 20 March 2018 Issue Published: 20 March 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...